November 18, 2026
Health news, explained with evidence
LIVE
Understanding and Addressing Love Handles Through Lifestyle Changes Ciele Releases New Woolmark-Certified Merino Winter Running Apparel Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine Understanding and Addressing Love Handles Through Lifestyle Changes Ciele Releases New Woolmark-Certified Merino Winter Running Apparel Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine

New RNA Switch Technology Allows Drugs to Control Gene Therapy Protein Production

🏥 Public Health 2 min read 👁 3

Bioengineers at the University of California San Diego have developed a novel RNA switch called an adaptamer, enabling small-molecule drugs to precisely regulate therapeutic protein production in cells.

New RNA Switch Technology Allows Drugs to Control Gene Therapy Protein Production🏥Public Health

Photo: Medical Xpress

Key points

  • UC San Diego bioengineers developed RNA 'adaptamers' to control gene therapy protein output.
  • The switch uses small-molecule drugs to activate or reduce protein production without altering the gene therapy itself.
  • Preclinical tests successfully reversed liver fat buildup and promoted weight loss using the metabolic protein FGF21.

Researchers at the University of California San Diego have created a new technology designed to make gene therapies safer and more adaptable. Led by bioengineering professor Prashant Mali and Ph.D. student Jack Bryant, the team developed short pieces of RNA known as adaptamers, short for ADAR-modulatable aptamers. These tools use small-molecule drugs to control when and how much cells produce therapeutic proteins.

Gene therapies typically deliver permanent genetic instructions to cells, which can make it difficult to manage protein levels over time. Because many therapeutic proteins carry risks if expressed at excessive levels or for too long, this new method offers a potential solution by letting clinicians adjust drug dosing to raise or lower protein output without removing the gene therapy.

In preclinical studies published in Molecular Cell, the team tested the adaptamer system to regulate the production of FGF21, a metabolic protein that helps combat obesity. The experiments showed that drug-activated protein production led to significant weight loss, better blood sugar regulation, and a near-complete reversal of liver fat accumulation. However, researchers emphasize that these findings are early-stage preclinical results, and further study is required to determine how precisely protein levels can be fine-tuned in clinical settings.

What to know: The adaptamer system acts as an adjustable molecular switch, using drugs like tetracycline or doxycycline to turn therapeutic protein production on or off as a patient's medical needs change. Always consult a qualified healthcare provider for personal medical decisions and advice regarding treatments.

Source Medical Xpress — medicalxpress.com/news/2026-11-rna-drugs-gene-therapy-protein.html ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.